Sentinel lymph node biopsy using periareolar injection of radiocolloid for patients with neoadjuvant chemotherapy–treated breast carcinoma
Open Access
- 2 June 2004
- Vol. 100 (12), 2555-2561
- https://doi.org/10.1002/cncr.20242
Abstract
BACKGROUND The feasibility and accuracy of sentinel lymph node (SLN) biopsy after neoadjuvant chemotherapy (NAC) for patients with breast carcinoma have been investigated primarily for the situation in which the radiocolloid imaging agent is injected peritumorally. No such study has involved periareolar injection of radiocolloid, although the usefulness of this injection technique has been demonstrated in patients with early-stage breast carcinoma who have not been treated with NAC. The objective of the current study was to determine the feasibility and accuracy of SLN biopsy using periareolar injection of radiocolloid for patients with breast carcinoma who were treated with NAC. METHODS Forty-seven patients with AJCC Stage II or III breast carcinoma who were treated with NAC were enrolled in the study. All patients underwent SLN biopsy, which involved a combination of periareolar injection of radiocolloid (technetium 99m tin colloid) and peritumoral injection of isosulfan blue dye, followed by backup axillary lymph node dissection. SLN metastases were examined by hematoxylin and eosin staining and immunohistochemical analysis using an anticytokeratin antibody. RESULTS An SLN was identified successfully in 44 patients (94%). Twenty-nine patients (66%) had positive SLNs. Fifteen patients had negative SLNs, and 4 patients had positive non-SLNs. Thus, the false-negative rate was 12.1% (4 of 33 patients). The false-negative rate tended to be higher, although not statistically significantly so, among patients who had clinically positive axillary lymph nodes before and/or after NAC (15.8%; 3 of 19 patients) compared with patients who had clinically negative axillary lymph nodes both before and after NAC (7.1%; 1 of 14 patients). CONCLUSIONS SLN biopsy using periareolar injection of radiocolloid is feasible after NAC. In patients with clinically negative axillary lymph nodes both before and after NAC, SLN biopsy was capable of predicting axillary lymph node status with an accuracy comparable to the accuracy associated with SLN biopsy for patients with early-stage carcinoma who have not been treated with NAC. Cancer 2004. © 2004 American Cancer Society.This publication has 24 references indexed in Scilit:
- Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancerAnnals of Surgical Oncology, 2002
- Is sentinel lymph node biopsy reliable and indicated after preoperative chemotherapy in patients with breast carcinoma?Cancer, 2001
- Increased false negative sentinel node biopsy rates after preoperative chemotherapy for invasive breast carcinomaCancer, 2000
- Preoperative lymphoscintigraphy during lymphatic mapping for breast cancer: improved sentinel node imaging using subareolar injection of technetium 99m sulfur colloidJournal of the American College of Surgeons, 2000
- Lessons Learned From 500 Cases of Lymphatic Mapping for Breast CancerAnnals of Surgery, 1999
- Immunohistochemistry with pancytokeratins improves the sensitivity of sentinel lymph node biopsy in patients with breast carcinomaCancer, 1999
- Optimal Histopathologic Examination of the Sentinel Lymph Node for Breast Carcinoma StagingThe American Journal of Surgical Pathology, 1999
- Sentinel-Lymph-Node Biopsy for Breast Cancer — Not Yet the Standard of CareNew England Journal of Medicine, 1998
- Guidelines for Sentinel Node Biopsy and Lymphatic Mapping of Patients With Breast CancerAnnals of Surgery, 1998
- Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodesThe Lancet, 1997